VivoSeq
Neurology

Spasticity

42

Pipeline Programs↗

9

Active Trials↗

20

Companies Involved↗

Spasticity is a moderately active landscape with 42 programs across 20 companies. The most active players are Saol Therapeutics Inc, PhytoTech Therapeutics, Ltd., Amphastar Pharmaceuticals, Inc.. 10 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

19/100

Mech. Concentration

29/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Saol Therapeutics Inc

1 program

Phase 2P

PhytoTech Therapeutics, Ltd.

1 program

Phase 2A

Amphastar Pharmaceuticals, Inc.

1 program

Phase 2Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

1 program

Phase 2R

Revance Therapeutics, Inc.

2 programs

Phase 2C

Chongqing Claruvis Pharmaceutical Co., Ltd.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical6

Incobotulinumtoxina

Merz Pharmaceuticals GmbH

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Botulinum Toxin a

GSK

Botulinum Toxin

Meshalkin Research Institute of Pathology of Circulation

Bont-a

Sir Run Run Shaw Hospital

Phase 14

Botox and Rehab

Emory University

CKDB-501A

CKD Bio Corporation

ABBV-950

AbbVie

HU-014

Huons Co., Ltd.

Phase 211

Hyaluronidase

Amphastar Pharmaceuticals, Inc.

IPN10200

Ipsen

Dysport

Ipsen

Sequence 2

Chong Kun Dang Pharmaceutical

DAXI 80 U

Revance Therapeutics, Inc.

Phase 311

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Arbaclofen

Seaside Therapeutics, Inc.

Botox

AbbVie

Sativex

Jazz Pharmaceuticals

SPARC0921

Sun Pharma Advanced Research Company Limited

Approved10

Baclofen

Novartis

Nabilone

Bausch Health Americas, Inc.

Tizanidine

Legacy Health System

Memantine

AbbVie

Intrathecal Baclofen

MedtronicNeuro

Analysis

Modality Breakdown

98%

Small molecule

47 of 48 classified programs — the dominant modality here.

2%ALL OTHERSProtein / enzyme12%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 98% of 58 pipeline programs.

Analysis

Trial Status

92

clinical trials

Completed61 · 66%
Unknown status16 · 17%
Recruiting5 · 5%
Withdrawn3 · 3%
Terminated3 · 3%
Not yet recruiting3 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

92 trials

Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity
Recruiting·UUniversiteit Antwerpen·Phase 2/3·NCT06296082·90 enrolled
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
Recruiting·CChongqing Claruvis Pharmaceutical Co., Ltd.·Phase 3·NCT07478822·300 enrolled
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
Recruiting·CChongqing Claruvis Pharmaceutical Co., Ltd.·Phase 2/3·NCT06783114·254 enrolled
Comparing Upper Limb Surgery and Botulinum Toxin for Spasticity: A Paired Design Study
Recruiting·—·N/A·NCT06733025·30 enrolled
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
Recruiting·Ipsen logoIpsen·Phase 1/2·NCT04752774·240 enrolled
A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity
Active, not recruiting·Ipsen logoIpsen·N/A·NCT06055725·1,058 enrolled
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .
Not yet recruiting·JJHM BioPharma (Tonghua) Co. , Ltd.·Phase 3·NCT07242300·207 enrolled
Effectiveness of an Interprofessional Approach to the Treatment of Spasticity With Botulinum Toxin & Non-pharmacological Therapies
Not yet recruiting·—·N/A·NCT07160699·30 enrolled
Collagenase Injection for Contracture and Spasticity Management
Not yet recruiting·TThe University of Texas Health Science Center, Houston·Phase 1·NCT07693569·15 enrolled
SISTERS: Spasticity In Stroke Study - Randomized Study
Completed·MMedtronicNeuro·Phase 4·NCT01032239·61 enrolled
Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients
Completed·EEmory University·Phase 1·NCT00565201·25 enrolled
Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)
Completed·GSK logoGSK·N/A·NCT01390922·1,038 enrolled
BTX-A and Mirror Therapy for Chronic Stroke Spasticity
Completed·FFatih Sultan Mehmet Training and Research Hospital·N/A·NCT07331844·30 enrolled
Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity
Completed·—·N/A·NCT00945295·31 enrolled
Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity
Completed·CCKD Bio Corporation·Phase 1·NCT05382767·24 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)